CTU Chad Therapeutics,

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant x
Filed by a Party other than the Registrant o

Check the appropriate box:

o		Preliminary Proxy Statement
o		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o		Definitive Proxy Statement
o		Definitive Additional Materials
x		Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-12

CHAD Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x		No fee required.
o		Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
			(1	)		Title of each class of securities to which transaction applies:
						N/A
			(2	)		Aggregate number of securities to which transaction applies:
						N/A
			(3	)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
						N/A
			(4	)		Proposed maximum aggregate value of transaction:
						N/A
			(5	)		Total fee paid:
						N/A
o		Fee paid previously with preliminary materials.
o		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
			(1	)		Amount previously paid:
						N/A
			(2	)		Form, Schedule or Registration Statement no.:
						N/A
			(3	)		Filing Party:
						N/A
			(4	)		Date Filed:
						N/A

 

 

CHAD Therapeutics Announces Mailing of Definitive Proxy
Regarding Proposed Sale of Its Oxygen Business

Sets Special Meeting of Shareholders for Thursday, January 31, 2008

CHATSWORTH, California, January 2, 2008 . . . CHAD Therapeutics, Inc. (ASE:CTU) announced today that it has commenced mailing its definitive proxy statement to shareholders for approval of its proposed sale of assets related to its oxygen conserving business to Inovo, Inc., a privately held manufacturer of oxygen regulators and conservers based in Naples, Florida, pursuant to an asset purchase agreement dated November 16, 2007. The Company has scheduled a special meeting of shareholders for Thursday, January 31, 2008, at 10:00 a.m. PST at CHAD Therapeutics, Inc, 21622 Plummer Street, Chatsworth, CA, 91311. Shareholders of record as of the close of business on December 24, 2007, will be entitled to vote at the meeting.

The Company’s Board of Directors has unanimously determined that the proposed asset sale is in the best interests of the Company and its shareholders and recommends that shareholders vote “FOR” the proposed sale.

Shareholders are encouraged to read the Company’s definitive proxy materials in their entirety. The proxy materials, which were mailed on or about December 28, 2007, provide, among other things, a detailed discussion of the process that led to the proposed asset sale, the reasons behind the Board of Directors’ unanimous recommendation and the risks involved with the sale. Additional copies of the proxy statement are available without charge from CHAD and also may be obtained for free from the SEC’s website at www.sec.gov . Stockholders who have questions about the asset sale or need assistance in submitting their proxy or voting their shares should contact the Company’s proxy solicitor, Morrow & Co., LLC, toll free at 1-800-662-5200.

Earl Yager, CHAD’s President and CEO said, “Approval of the asset sale is critical to CHAD’s future. Because failure to vote will have the same effect as a vote against approving the transaction, we urge shareholders to exercise their rights by voting their shares as soon as possible after they receive and review the proxy statement.”

About CHAD Therapeutics

CHAD Therapeutics, Inc. develops, manufactures and markets respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com .

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.

The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the loss of one or more major customers, increased competition, the introduction of new products with perceived competitive advantages over the Company’s products, changes or proposed changes in health care reimbursement which affect home care providers and CHAD’s ability to anticipate and respond to technological and economic changes in the home oxygen market. Moreover, the success of the Company’s products and products under development will depend on their efficacy, reliability and the health care community’s perception of the products’ capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company’s annual and quarterly reports filed with the Securities and Exchange Commission under the caption “Outlook: Issues and Risks.”

* * * * *

#4471

CHAD, OXYMATIC, OXYMIZER, OXYLITE, and TOTAL O ₂ are Registered Trademarks of Chad Therapeutics, Inc.
ISO 13485 Certified Company
WWW.CHADTHERAPEUTICS.COM

Chad Therapeutics (AMEX:CTU)
Historical Stock Chart
From Nov 2024 to Dec 2024

Chad Therapeutics (AMEX:CTU)
Historical Stock Chart
From Dec 2023 to Dec 2024